ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1145

Human Cardiovascular Disease Model Provides Transcriptomic Evidence of Cardiovascular Risk Associated with Febuxostat

Ryan Feaver1, Scott Bowers2, Banumathi Cole1, Steve Hoang1, Mark Lawson1, Justin Taylor1, Brian LaMoreaux2, Lin Zhao2, Brad R Henke1, Brian Johns1, Andrew C Nyborg2, Brian R Wamhoff1 and Rob Figler1, 1HemoShear Therapeutics, Charlottesville, VA, 2Horizon Therapeutics, Deerfield, IL

Meeting: ACR Convergence 2023

Keywords: Bioinformatics, Cardiovascular, gout, hyperuricemia, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is a chronic inflammatory arthritis that is undertreated and managed with the xanthine oxidase inhibitors febuxostat or allopurinol. Despite the United States Food and Drug Administration (FDA) mandating febuxostat carry its most prominent warning for serious side effects that include cardiovascular-related death, febuxostat is widely prescribed. A large, manufacturer-sponsored clinical trial (CARES) led to the febuxostat FDA warning label; however, a recent, large clinical trial (FAST) did not replicate these data in patients without pre-existing cardiovascular risk. Whether febuxostat increases cardiovascular risk remains an important question and to date there are few mechanistic studies designed to resolve this controversy.

Methods: We compared the transcriptomic signature of oral gout medications alongside 107 other clinical stage compounds, 33 of which are FDA labelled for increased cardiovascular risk, in an in vitro human primary cell-based cardiovascular disease model to clarify the potential risk of febuxostat.

Results: Febuxostat significantly modulated more signaling pathways associated with cell stress and cardiovascular risk than allopurinol or topiroxostat, gout medications not associated with increased cardiovascular risk. Moreover, these signaling pathways were commonly regulated by other drugs FDA labelled for cardiovascular risk. Lastly, these results were replicated with a febuxostat analog.

Conclusion: Together, these data support the FDA warning for febuxostat and suggest that cardiovascular risk associated with gout medications stems from chemical structure of the medication, itself, rather than the target, xanthine oxidase.


Disclosures: R. Feaver: HemoShear Therapeutics, 3, 3, 8, 8, 10, 11, 11; S. Bowers: Horizon Therapeutics, 3; B. Cole: None; S. Hoang: HemoShear Therapeutics, 3, 11; M. Lawson: Hemoshear Therapeutics, 3, 11; J. Taylor: HemoShear Therapeutics, 3, 8, 11; B. LaMoreaux: Horizon Therapeutics, 3, 11; L. Zhao: Horizon Therapeutics, 3; B. Henke: GlaxoSmithKlein(GSK), 8, 10, 11, HemoShear Therapeutics, 3, 8, 11; B. Johns: GlaxoSmithKlein(GSK), 3, 8, 10, 11, HemoShear Therapeutics, 3, 8, 11; A. Nyborg: None; B. Wamhoff: HemoShear Therapeutics, 3, 8, 10, 11; R. Figler: HemoShear Therapeutics, 3.

To cite this abstract in AMA style:

Feaver R, Bowers S, Cole B, Hoang S, Lawson M, Taylor J, LaMoreaux B, Zhao L, Henke B, Johns B, Nyborg A, Wamhoff B, Figler R. Human Cardiovascular Disease Model Provides Transcriptomic Evidence of Cardiovascular Risk Associated with Febuxostat [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/human-cardiovascular-disease-model-provides-transcriptomic-evidence-of-cardiovascular-risk-associated-with-febuxostat/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/human-cardiovascular-disease-model-provides-transcriptomic-evidence-of-cardiovascular-risk-associated-with-febuxostat/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology